title: Cost-effectiveness of venous thromboembolism prophylaxis with a new mobile device after total hip arthroplasty.
abstract: Recent comparison (SAFE study) of a mobile, synchronized compression device and low-molecular-weight heparin for prophylaxis of venous thromboembolism showed similar efficacy but significant differences in major bleeding. A model was constructed to evaluate any difference in cost-effectiveness between the 2 therapies incorporating rates and probabilities of major bleeding from the SAFE study with published costs for treating those adverse events. Evaluation of the cost-effectiveness of each therapy was performed and applied to hypothetical patient populations representative of annual health system volume. The model showed a cost-effectiveness advantage of the compression device resulting in a savings of more than $3.69 million in a 10 000-patient cohort. The result was primarily driven by a decrease in the amount of major bleeding, which requires significant health care resources to treat.
authors.affiliation: Shiley Center for Orthopaedic Research & Education at Scripps Clinic, La Jolla, CA, USA.
mesh_terms: D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D006801:Humans; D008962:Models, Theoretical; D015912:Thrombolytic Therapy / Q000191:economics / Q000295:instrumentation; D054556:Venous Thromboembolism / Q000191:economics* / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants